Nasdaq:SKYE
Skye Bioscience, Inc.
A preclinical-stage biopharma developing novel cannabinoid receptor agonist therapies for CNS disorders like Alzheimer's and pain.
Key Metrics
Investment Thesis
Bull Case
Investors may be attracted by the potential for a first-in-class asset class in the cannabinoid space targeting lucrative CNS indications with massive market opportunities. The company's recent successful financing events suggest confidence from institutional partners and provide a runway to advance key candidates into clinical trials. If any pipeline assets demonstrate proof-of-concept efficacy, the value accretion could be exponential given the current pre-market status.
Bear Case
The total absence of revenue and a growing retained earnings deficit of over $130M presents a severe liquidity risk that requires continuous capital raising. The company's operating cash flow is negative at -$25.2M, indicating high burn rates that could deplete remaining cash reserves quickly without successful commercialization milestones. High dilution from share issuances and lack of product market fit validation make the stock speculative and prone to volatility.
About Skye Bioscience, Inc.
Skye Bioscience is a preclinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders such as Alzheimer's disease and pain. The company operates in the United States and has a pipeline centered on its proprietary CB1/CB2 cannabinoid receptor agonists, aiming to address significant unmet medical needs with innovative small molecule drugs.
Analysis
Management Discussion
Skye Bioscience reported a net loss of $26.6M for the latest year, continuing a trend of significant operating losses from -$19.5M in 2022 to -$37.6M in 2023 before narrowing slightly. Despite these losses, the company maintained strong liquidity with approximately $68.4M in cash and equivalents, bolstered by substantial financing cash flows of $83.6M during the period, allowing it to sustain its R&D efforts.
Industry Overview
The biopharmaceutical sector for central nervous system disorders is highly competitive but offers substantial value, with Alzheimer's disease alone representing a multi-billion dollar addressable market. Regulatory pathways for CNS drugs are stringent and costly, favoring companies with robust clinical trial data and deep pockets, which challenges preclinical-stage firms like Skye Bioscience.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $18.3M | $34.7M | $30.2M |
| Operating Income | $-18.3M | $-34.7M | $-30.2M |
| R&D | $6.0M | — | — |
| G&A | $6.1M | $7.9M | $17.7M |
| Stock-Based Comp | $629.0K | $987.5K | $8.3M |
| D&A | — | — | $298.6K |
| Depreciation | $115.0K | $124.3K | $203.8K |
| Other OpEx | $6.2M | $26.9M | $12.5M |
| Non-Operating Income | $-1.2M | $-2.9M | $3.6M |
| Interest Expense | $665.1K | $906.3K | $749.3K |
| Interest Income | $19.0K | $100.0K | $3.0M |
| Pre-Tax Income | $-19.5M | $-37.6M | $-26.6M |
| Income Tax | $6.7K | $3.6K | $10.1K |
| Continuing Ops | $-19.5M | $-37.6M | $-26.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-19.5M | $-37.6M | $-26.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-19.5M | $-37.6M | $-26.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $8.9M | $11.7M | $70.8M |
| Cash & Equivalents | — | — | $68.4M |
| Other Current Assets | — | — | $2.4M |
| Long-Term Assets | $167.4K | $289.6K | $1.9M |
| PP&E (Net) | $87.9K | $43.3K | $1.4M |
| Operating Leases | $71.2K | $238.0K | $449.9K |
| Other LT Assets | $8.3K | $8.3K | $53.9K |
| Total Assets | $9.1M | $11.9M | $72.8M |
| Current Liabilities | $12.1M | $13.9M | $4.3M |
| Accounts Payable | $1.7M | — | — |
| Current Leases | $78.7K | $72.0K | $182.4K |
| Other Current Liab | $10.4M | $13.8M | $4.2M |
| Long-Term Liabilities | $0 | $171.2K | $273.2K |
| LT Operating Leases | $0 | $171.2K | $273.2K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $12.1M | $14.1M | $4.6M |
| Shareholders' Equity | $-3.0M | $-2.1M | $68.2M |
| Retained Earnings | $-66.7M | $-104.4M | $-130.9M |
| Total L&E | $9.1M | $11.9M | $72.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-19.5M | $-37.6M | $-26.6M |
| Non-Cash Adjustments | $7.7M | $25.1M | $660.6K |
| Working Capital Changes | $-968.4K | $-1.4M | $669.1K |
| Cash from Operations | $-12.7M | $-14.0M | $-25.2M |
| Capital Expenditures | $28.1K | $12.6K | $1.6M |
| Cash from Investing | $5.2M | $6.6M | $-245.6K |
| Cash from Financing | $-208.8K | $16.4M | $83.6M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-7.7M | $9.1M | $58.1M |
| Beginning Cash | $9.0M | $1.2M | $10.3M |
| Ending Cash | $1.2M | $10.3M | $68.4M |
Frequently Asked Questions
How does Skye Bioscience, Inc. make money?
The company operates primarily through its drug discovery and development segment, which focuses on the research, development, and potential commercialization of proprietary therapeutics. Given the lack of revenue in recent years, all financial activity is driven by internal R&D initiatives and strategic financing rather than multiple product lines or geographical segments.
What are the main risks for SKYE?
The company has no revenue and a significant accumulated deficit, indicating it is highly dependent on future financing to fund operations. As a preclinical-stage entity, the success of its drug candidates remains unproven and faces high attrition risks typical of early biotech development. The burn rate is substantial relative to cash reserves, creating liquidity pressure if external funding markets tighten or milestone payments are delayed.
What is SKYE's competitive advantage?
The company possesses a unique pipeline of first-in-class small molecule CB1/CB2 receptor agonists that offer distinct pharmacological profiles compared to existing treatments. Its proprietary intellectual property portfolio protects these novel mechanisms of action, while its focus on CNS disorders targets high-value markets with significant unmet medical needs.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.